Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Akt/NF-κB/MAPK-IN-1 (compound 2m) serves as a potent, orally active inhibitor targeting NO with an IC50 of 7.70 μM and demonstrates low toxicity. This compound exerts anti-inflammatory effects by impeding the Akt/NF-κB and MAPK signaling pathways [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Akt/NF-κB/MAPK-IN-1 (compound 2m) serves as a potent, orally active inhibitor targeting NO with an IC50 of 7.70 μM and demonstrates low toxicity. This compound exerts anti-inflammatory effects by impeding the Akt/NF-κB and MAPK signaling pathways [1]. |
In vitro | Akt/NF-κB/MAPK-IN-1 (compound 2m) at concentrations ranging from 0 to 20 μM over 24 hours significantly reduced the levels of TNF-α, IL-1β, IL-6, and PGE2, as well as downregulated the expression of iNOS and COX-2 in LPS (10 ng/mL)-stimulated RAW264.7 cells [1]. Furthermore, this compound inhibited the phosphorylation of p38, ERK, and JNK in the LPS-induced RAW264.7 cells [1]. |
In vivo | Akt/NF-κB/MAPK-IN-1 (compound 2m) administered orally at a dosage of 10-20mg/kg for a consecutive 7 days can alleviate LPS-induced inflammatory disease in mice [1]. |
Molecular Weight | 604.86 |
Formula | C38H56N2O4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Akt/NF-κB/MAPK-IN-1 MAPK p38 MAPK inhibitor inhibit